Why Nostr? What is Njump?
2025-05-18 05:54:33
in reply to

finance.yahoo.com on Nostr: finance.yahoo.com ✍️ Iovance Biotherapeutics' shares fell 6% after an analyst ...



✍️ Iovance Biotherapeutics' shares fell 6% after an analyst downgraded his recommendation to neutral from buy, citing concerns over the company's latest quarterly earnings report.
👉 Analyst David Dai downgraded Iovance Biotherapeutics' recommendation to neutral from buy
👉 Price target lowered to $2 per share from $17
👉 Below-expectation sales of advanced melanoma drug Amtagvi
👉 Higher drop-out rates for the drug
👉 Slow ramp-up of commercialization
👉 Flaws in patient selection
👉 Revenue guidance cut in earnings report

#DavidDai #EricVolkman #business

https://s.yimg.com/ny/api/res/1.2/W2IgyITSOXNnFeA265JwxQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/0a886363d77cee337ab330e5d82d25cb

https://finance.yahoo.com/news/why-iovance-biotherapeutics-tumbled-nearly-223909778.html

Author Public Key
npub1g8g50xheecekjh2qvhzwvqqycmwfy2kmlnqhv0nfj0qf48dhr0rst3ldht